Milken Institute Panels

2017 Global Conference

Supercharge the Search for Cures: Medical Philanthropists Reinvent Giving to Get Results

Leverage: How Philanthropies Use New Tools to Create Change

Mission Driven: How NextGen Leaders Use Business Tools to Create Social Change

Seeding Change: A New Dynamism in Philanthropy

Past Summits

How Philanthropic Capital Can Spark 21st Century Innovations This session showcases promising solutions being advanced across a range of sectors and geographies, including mission-related investments, social impact bonds, venture philanthropy, outcome-sensitive metrics, and public-private partnerships.

How Philanthropic Capital Can Spark 21st Century Innovations

This session showcases promising solutions being advanced across a range of sectors and geographies, including mission-related investments, social impact bonds, venture philanthropy, outcome-sensitive metrics, and public-private partnerships.

New Wave Giving: How the Next Generation of Philanthropists is Rethinking the Model   What happens when you mix next-generation energy and ingenuity with philanthropic capital? The answer is you get innovations that bring a business sense — and greater impact — to charitable giving.

New Wave Giving: How the Next Generation of Philanthropists is Rethinking the Model 

What happens when you mix next-generation energy and ingenuity with philanthropic capital? The answer is you get innovations that bring a business sense—and greater impact—to charitable giving.

European Philanthropy's Role in Addressing Global Challenges   The 21st century has seen a surge of philanthropy in Europe, evidenced by a significant rise in individual philanthropists and foundation activity. 

European Philanthropy's Role in Addressing Global Challenges
 

The 21st century has seen a surge of philanthropy in Europe, evidenced by a significant rise in individual philanthropists and foundation activity. 

Activist Philanthropy: Upping the Ante for Giving A new generation of donors is changing philanthropy. Accustomed to solving problems and driving change, they aren't waiting for retirement to begin sharing vast portions of their fortunes to meet worthy goals.

Activist Philanthropy: Upping the Ante for Giving

A new generation of donors is changing philanthropy. Accustomed to solving problems and driving change, they aren't waiting for retirement to begin sharing vast portions of their fortunes to meet worthy goals.

Strategic Advocacy: Persuading People to Care Solving the world's most intractable problems isn't just about great ideas and great intentions—it requires a bolder way of thinking and doing. The most effective change-makers have learned to use their influence and resources in innovative ways to inspire others to join the crusade.

Strategic Advocacy: Persuading People to Care

Solving the world's most intractable problems isn't just about great ideas and great intentions—it requires a bolder way of thinking and doing. The most effective change-makers have learned to use their influence and resources in innovative ways to inspire others to join the crusade.

Interviews

Cara Altimus on Alzheimer's Research AL JAZEERA Cara Altimus, Associate Director at CSP, speaks about Pfizer's decision to divest in neurodegenerative disease research.  

Cara Altimus on Alzheimer's Research
AL JAZEERA

Cara Altimus, Associate Director at CSP, speaks about Pfizer's decision to divest in neurodegenerative disease research.  

 
Helping the Wealthy Give Away their Millions CNBC Melissa Stevens sat down with CNBC's Robert Frank to talk about the newest efforts to help individuals build high-impact philanthropy portfolios.

Helping the Wealthy Give Away their Millions
CNBC

Melissa Stevens sat down with CNBC's Robert Frank to talk about the newest efforts to help individuals build high-impact philanthropy portfolios.

M elissa Stevens and Alexis Ohanian FACEBOOK LIVE LIVE from #MIGlobal :  Reddit 's co-founder Alexis Ohanian and Milken Institute's Melissa Stevens.

Melissa Stevens and Alexis Ohanian
FACEBOOK LIVE

LIVE from #MIGlobal: Reddit's co-founder Alexis Ohanian and Milken Institute's Melissa Stevens.

 
Private Foundations: Searching for the sweet spot FINANCIAL TIMES Families search for the sweet spot in medical research

Private Foundations: Searching for the sweet spot

FINANCIAL TIMES

Families search for the sweet spot in medical research

C indy Whitehead and NV Tyagarajan FACEBOOK LIVE Milken Institute's Melissa Stevens is LIVE with The Pink Ceiling 's Cindy Whitehead and Genpact 's NV "Tiger" Tyagarajan.  #MIGlobal

Cindy Whitehead and NV Tyagarajan
FACEBOOK LIVE

Milken Institute's Melissa Stevens is LIVE with The Pink Ceiling's Cindy Whitehead and Genpact's NV "Tiger" Tyagarajan. #MIGlobal

 
Seeing the Big Picture THE BUSINESS TIMES The Milken Institute champions a problem solving approach to giving.

Seeing the Big Picture

THE BUSINESS TIMES

The Milken Institute champions a problem solving approach to giving.

B uilding Meaningful Lives FACEBOOK LIVE LIVE at #MIGlobal : Charity Network's Todd Wagner and Melissa Stevens discuss building meaningful lives.

Building Meaningful Lives
FACEBOOK LIVE

LIVE at #MIGlobal: Charity Network's Todd Wagner and Melissa Stevens discuss building meaningful lives.

 
Michael Milken LIFESTYLES MAGAZINE This genius game changer is saving lives by accelerating medical solutions worldwide.

Michael Milken

LIFESTYLES MAGAZINE

This genius game changer is saving lives by accelerating medical solutions worldwide.

Opinion

Research foundations: Philanthropic risks can hit home runs  

Nature
Melissa Stevens

As an adviser to medical-research foundations on effective donation, I contend that philanthropic capital has an intrinsic advantage over public funding: it thrives on risk. This encourages the testing of bold ideas, even when there's a high chance they might not work out.

Financing High-Risk Medical Research  

MILKEN INSTITUTE REVIEW
Melissa Stevens

In the past few years, the media has showered us with headlines about record-setting biotech financing—outsized venture-capital rounds, unprecedented public market appetite for IPOs, and robust sector returns. But a closer look suggests there is more froth than substance at this frontier of medicine and science.